Abstract:We read with interest the article by De Salvo et al,1De Salvo C. et al.Gastroenterology. 2021; 160: 302-316 e7Abstract Full Text Full Text PDF PubMed Scopus (5) Google Scholar which suggested a potential role for eosinophils during the process of metaplasia triggered by IL-33 in a chronic model of gastritis-prone mice. The mechanisms responsible for the progression of metaplastic mucosa to dysplasia and cancer have always been the central problem in tumor research field. Through the use of mouse model and neutralization antibodies, the authors clearly demonstrated the importance of IL-33/ST2 axis in the development of chronic inflammation and metaplasia in the stomach. In addition, the current study also implicated eosinophils as an early, IL-33–responsive innate immune cell population that participated in the complex orchestration leading to spasmolytic polypeptide-expressing metaplasia (SPEM)/intestinalized SPEM. However, combining previous results and current results by the same group,1De Salvo C. et al.Gastroenterology. 2021; 160: 302-316 e7Abstract Full Text Full Text PDF PubMed Scopus (5) Google Scholar, 2Petersen C.P. et al.Gut. 2018; 67: 805-817Crossref PubMed Scopus (38) Google Scholar, 3Petersen C.P. et al.Gastroenterology. 2014; 146: 1727-17238 e8Abstract Full Text Full Text PDF PubMed Scopus (59) Google Scholar we still would like to raise the following concerns. First, if the SPEM process is induced by an early eosinophil-dependent response, the neutralization of eosinophils should result in a dramatical decrease in the following events, including gastric inflammation and M2 macrophage infiltration. Anti–IL-5 treatment efficiently decreased the numbers of eosinophils, both in the peripheral and local environments, as expected. However, anti–IL-5 treatment only partially decreased gastric inflammation and M2 macrophage infiltration, which was more profound in anti-CCR3 treatment, especially for the control of M2 infiltration. Of note, CCR3 can also be expressed on M2 macrophages. The application of anti-CCR3, which was originally used for the purpose of eosinophil depletion, seemed to be more efficient in depleting local M2 macrophages, with less efficiency in depleting eosinophils compared with that of anti–IL-5 treatment. Therefore, the effects exerted by anti-CCR3 treatment may largely due to its direct impact on M2 macrophages. In addition, although anti–IL-5 treatment efficiently depleted eosinophils in the current study, it did not reverse the decrease of Mist1 expression. Anti-CCR3 treatment alone could slightly increase the expression of Mist1, suggesting a more critical role of M2 macrophages in driving chief cell transdifferentiation, but not eosinophils. This finding was consistent with previous studies by the same group, demonstrating a similar role of macrophages in chemical drug-induced metaplasia model. Since eosinophils were absent in IL33–/– mice, it would be interesting to further assess the pathologic changes and M2 macrophage infiltration in SAMPxIL33–/– mice to confirm these. Second, ILC2s are the major producers of IL-5 in response to IL-33 stimulation, which has been suggested to play a central role in eosinophil homeostasis.4Nussbaum J.C. et al.Nature. 2013; 502: 245-248Crossref PubMed Scopus (579) Google Scholar With the use of Rag2–/– mice lacking T/B cells but with intact ILC function, the authors suggested a negligible role of ILCs in SPEM development; they found almost a complete loss of gastric inflammation and epithelial hyperplasia with normal stomachs in SAMPxRag2–/– mice. However, these results, at the same time, raised a possible concern that adaptive immunity may actually have an indispensable role in SPEM development, partly challenging current conclusion of eosinophil-dependent events in driving metaplasia. The authors may not rule out the possibility that resident Th2 and Treg cells may respond to IL-33 stimuli early and lead to the following events identified in the current study. Although a different mouse model was used, a previous study by the same group has indicated the importance of Th2-related cytokines in the development of metaplasia, especially for IL-13.2Petersen C.P. et al.Gut. 2018; 67: 805-817Crossref PubMed Scopus (38) Google Scholar Thus, it would be interesting to further assess the peripheral number and infiltration of eosinophils in the stomach of SAMPxRag2–/– mice to see the impact of adaptive immunity on eosinophils. Third, how about the role of mast cells in IL-33 driven metaplasia? Mast cells also express ST2, enabling them responding to IL-33 stimuli, and studies have shown an early increase of mast cells in the gastric submucosa before the onset of intestinal-type gastric tumor formation.5Eissmann M.F. et al.Nat Commun. 2019; 10: 2735Crossref PubMed Scopus (36) Google Scholar After stimulated by IL-33, mast cells can also produce IL-5 and other macrophage-attracting chemokines, which can promote the infiltration of M2 macrophages. It is also notable that mast cells also express CCR3.6Humbles A.A. et al.Proc Natl Acad Sci U S A. 2002; 99: 1479-1484Crossref PubMed Scopus (335) Google Scholar Therefore, current study may not rule out a possible role of mast cells in driving gastric metaplasia. However, as mentioned, because SAMPxRag2–/– mice displayed normal stomachs in which mast cells were not affected by the genetic deletion of Rag2–/–, mast cells may still need the help of adaptive immunity to exert their function even if they did paly a nonredundant role in the development of gastric metaplasia. In general, De Salvo et al1De Salvo C. et al.Gastroenterology. 2021; 160: 302-316 e7Abstract Full Text Full Text PDF PubMed Scopus (5) Google Scholar provided interesting results on the critical role of IL-33 in the development of chronic inflammation and metaplasia in the stomach. More insightful information on the cellular source responsible for the effects of IL-33/ST2 axis in different gastric metaplasia animal model may better benefit future targeted therapies to reverse gastritis and intestinalized SPEM and also to maintain immune homeostasis to avoid unwanted side effects. Interleukin 33 Triggers Early Eosinophil-Dependent Events Leading to Metaplasia in a Chronic Model of Gastritis-Prone MiceGastroenterologyVol. 160Issue 1PreviewInterleukin (IL)33/IL1F11 is an important mediator for the development of type 2 T-helper cell (Th2)–driven inflammatory disorders and has also been implicated in the pathogenesis of gastrointestinal (GI)-related cancers, including gastric carcinoma. We therefore sought to mechanistically determine IL33’s potential role as a critical factor linking chronic inflammation and gastric carcinogenesis using gastritis-prone SAMP1/YitFc (SAMP) mice. Full-Text PDF ReplyGastroenterologyVol. 160Issue 7PreviewWe read with perplexity the concerns raised by Du et al in regards to our recent publication.1 The authors contend 2 general points. First, that IL-33–responsive cells beyond eosinophils contribute to spasmolytic polypeptide-expressing metaplasia (SPEM), with their focus particularly on M2 macrophages. Second, the use of SAMP1/YitFc (SAMP) mice as a model of chronic, inflammation-driven gastric metaplasia in that “more insightful information” may be gained regarding “the effects of (the) IL-33/ST2 axis in a different gastric metaplasia animal model” that “may better benefit future targeted therapies.” We would like to emphasize that the overall goal of our study was to report that IL-33 serves as an important mediator linking inflammation and metaplasia, and identify IL-33–dependent eosinophil expansion and recruitment as a potential mechanism leading to SPEM in gastritis-prone SAMP, which we also introduced as a useful model/tool for this area of investigation. Full-Text PDF

Single-cell transcriptional analyses of spasmolytic polypeptide-expressing metaplasia arising from acute drug injury and chronic inflammation in the stomach

Single-Cell Transcriptional Analyses Identify Lineage-Specific Epithelial Responses to Inflammation and Metaplastic Development in the Gastric Corpus

Role of Spasmolytic Polypeptide-Expressing Metaplasia in Gastric Mucosal Diseases.

Role of metaplasia during gastric regeneration

Injury, repair, inflammation and metaplasia in the stomach.

Evidence for Heightened Genetic Instability in Precancerous Spasmolytic Polypeptide Expressing Gastric Glands

Deoxycholic acid-stimulated macrophage-derived exosomes promote spasmolytic polypeptide-expressing metaplasia in the stomach

Interleukin 13 Promotes Maturation and Proliferation in Metaplastic Gastroids

417 ANKRD22 AS A PROMISING THERAPEUTIC TARGET FOR RAPID RECRUITMENT OF LGR5+ STEM CELLS IN GASTRIC MUCOSAL BARRIER INJURY

Global knowledge mapping and emerging trends in research between spasmolytic polypeptide-expressing metaplasia and gastric carcinogenesis: A bibliometric analysis from 2002 to 2022

YAP targetome reveals activation of SPEM in gastric pre-neoplastic progression and regeneration

SOX9 governs gastric mucous neck cell identity and is required for injury-induced metaplasia

Clinical Significance of Spasmolytic Polypeptide-Expressing Metaplasia and Intestinal Metaplasia in Epstein-Barr Virus–associated and Epstein-Barr Virus–negative Gastric Cancer

IL-10 Plays a Pivotal Role in Tamoxifen-Induced Spasmolytic Polypeptide-Expressing Metaplasia in Gastric Mucosa

Single Cell Integration Characterises Metaplasia in Inflammatory Intestinal Diseases

Role and research progress of spasmolytic polypeptide‐expressing metaplasia in gastric cancer (Review)

The Cxcr2+ subset of the S100a8+ gastric granylocytic myeloid-derived suppressor cell population (G-MDSC) regulates gastric pathology

H. Pylori‐Facilitated TERT/Wnt/β‐Catenin Triggers Spasmolytic Polypeptide‐Expressing Metaplasia and Oxyntic Atrophy

Helicobacter pylori plays a key role in gastric adenocarcinoma induced by spasmolytic polypeptide-expressing metaplasia

IL-33 in Gastric Metaplasia—Implications for Therapeutic Targets

Combining transcriptomics and network pharmacology to reveal the mechanism of Zuojin capsule improving spasmolytic polypeptide-expressing metaplasia